TransMedics reported Q1 2026 adjusted EPS of $0.30, missing consensus $0.62 by $0.32.
Revenue rose 21% YoY to $173.9 million, slightly below the $174.47 million estimate.
Shares fell 22.5% in after‑hours trading after the earnings miss.
Company reaffirmed FY2026 revenue guidance of $727‑$757 million, mid‑point $742 million exceeding consensus $739 million.